文献速递消化系统肿瘤

TAS-102联合或不联合贝伐珠单抗治疗化疗难治性转移性结直肠癌:研究者发起的开放标签随机2期试验

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2020-01-27

该研究者发起的开放标签随机2期试验在丹麦四家癌症中心纳入93例化疗难治性转移性结直肠癌患者,1:1随机接受TAS-102单药或联合贝伐珠单抗治疗。联合方案可能成为难治性转移性结直肠癌的新治疗选择。

要点

  • TAS-102联合贝伐珠单抗较单药显著改善化疗难治性转移性结直肠癌的无进展生存期。
  • 联合组3级及以上中性粒细胞减少发生率67%,高于单药组的38%。

核心结论

  • 在化疗难治性转移性结直肠癌患者中,TAS-102联合贝伐珠单抗较TAS-102单药显著且具有临床意义地改善无进展生存期,毒性可耐受。

研究设计与样本

  • 研究者发起的开放标签随机2期试验,在丹麦四家癌症中心纳入93例化疗难治性转移性结直肠癌患者,1:1随机接受TAS-102单药(n=47)或联合贝伐珠单抗(n=46)。
  • 主要终点为研究者评估的无进展生存期,分析基于意向治疗人群,随机化按机构和RAS突变状态分层。

主要发现

  • 最常见的3级及以上不良事件为中性粒细胞减少,TAS-102单药组18/47(38%),联合组31/46(67%)。
  • 严重不良事件在TAS-102组21例(45%),联合组19例(41%),未观察到治疗相关死亡。

临床怎么用

  • 对于化疗难治性转移性结直肠癌患者,TAS-102联合贝伐珠单抗可考虑作为新的治疗选择,需关注中性粒细胞减少的监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer. Inspired by the encouraging results of a small phase 1-2 study, C-TASK FORCE, which evaluated the combination of TAS-102 plus bevacizumab in patients with chemorefractory metastatic colorectal cancer, we aimed to compare the efficacy of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients receiving refractory therapy for metastatic colorectal cancer . METHODS: This investigator-initiated, open-label, randomised, phase 2 study enrolled patients (aged ≥18 years) with metastatic colorectal from four cancer centres in Denmark. The main inclusion criteria were histopathologically confirmed metastatic colorectal cancer refractory or intolerant to a fluoropyrimidine, irinotecan, oxaliplatin, and cetuximab or panitumumab (only for RAS wild-type), and WHO performance status of 0 or 1. Previous therapy with bevacizumab, aflibercept, ramucirumab, or regorafenib was allowed but not mandatory. Participants were enrolled and randomly assigned (1:1) in block sizes of two, four, or six by a web-based tool to receive oral TAS-102 (35 mg/m2 twice daily on days 1-5 and 8-12 every 28 days) alone or combined with intravenous bevacizumab (5 mg/kg on days 1 and 15) until progression, unacceptable toxicity, or patient decision to withdraw. Treatment assignment was not masked, and randomisation was stratified by institution and RAS mutation status. The primary endpoint was investigator-evaluated progression-free survival. All analyses were based on intention to treat. This trial is registered with EudraCT, 2016-005241-23. FINDINGS: From Aug 24, 2017, to Oct 31, 2018, 93 patients were enrolled and randomly assigned to TAS-102 (n=47) or TAS-102 plus bevacizumab (n=46). The clinical cut-off date was Feb 15, 2019, after a median follow-up of 10·0 months (IQR 6·8-14·0). Median progression-free survival was 2·6 months (95% CI 1·6-3·5) in the TAS-102 group versus 4·6 months (3·5-6·5) in the TAS-102 plus bevacizumab group (hazard ratio 0·45 [95% CI 0·29-0·72]; p=0·0015). The most frequent grade 3 or worse adverse event was neutropenia (18 [38%] of 47 in the TAS-102 monotherapy group vs 31 [67%] of 46 in the TAS-102 plus bevacizumab group). Serious adverse events were observed in 21 (45%) patients in the TAS-102 group and 19 (41%) in the TAS-102 plus bevacizumab group. No deaths were deemed treatment related. INTERPRETATION: In patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab, as compared with TAS-102 monotherapy, was associated with a significant and clinically relevant improvement in progression-free survival with tolerable toxicity. The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development. FUNDING: Servier.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020. PMID: 31999946. doi:10.1016/S1470-2045(19)30827-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。